Sample Size and Power
Cross-source consensus on Sample Size and Power from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Dosage & preparation
Evidence quality
Highlighted claims
- The trial plans 20 active hospitals and a total sample size of 20,000 patients. — Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial
- The trial has 89.5% power to detect a reduction in 90-day readmission from 16.7% to 13.7%. — Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial
- The internal pilot uses Step 1 hospitals and enrolment over three months. — Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial
- The internal pilot classifies green status as an average of 200 patients per hospital, amber as 150 to 199 patients, and red as fewer than 150 patients. — Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial
- About 10% of patients or consultees are expected to consent to additional patient-reported outcome data, based on the feasibility study. — Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial